Patient Perspectives on Symptoms, Health-Related Quality of Life, and Treatment Experience Associated with Relapsed/Refractory Multiple Myeloma

Abstract Purpose: This study aimed to better understand the patient perspective on relapsed and/or refractory multiple myeloma (RRMM) treatment.Methods: This non-interventional, cross-sectional study enrolled adult RRMM patients from 6 US clinics who had ≥3 months of life expectancy, ≤6 prior lines of therapy, and ≥1 treatment regimen with a proteasome inhibitor and immunomodulator, or a CD38 monoclonal antibody or an alkylating agent, and a steroid. In-person semi-structured qualitative interviews were conducted to capture concepts that were relevant and important to patients. Topics included RRMM symptoms and impacts and the mode of administration, frequency, duration, convenience, side effects, and overall experience with RRMM treatment.Results: Twenty-two patients completed interviews. At enrollment, 59.1% of participants were using regimens containing dexamethasone, 36.4% daratumumab, 27.3% carfilzomib, and 18.2% lenalidomide. More participants had experience using intravenous or injectable therapy alone (40.9%) than oral therapy alone (18.2%). Back pain and fatigue were the most frequently reported symptoms (40.9% each); 27.3% reported no symptoms. Most participants reported physical function limitations (86.4%), emotional impacts (77.3%), MM-related activity limitations (72.7%), and sleep disturbances (63.6%). Most participants perceived treatment effectiveness based on physician-explained clinical signs (68.2%) and symptom relief (40.9%). Participants experienced gastrointestinal side effects (59.1%), fatigue (59.1%), sleep disturbances (31.8%), and allergic reactions (31.8%) with treatment. Key elements of treatment burden included the duration of a typical treatment day (68.2%), treatment interfering with daily activities (54.5%), and infusion duration (50.0%).Conclusions: These results provide treatment experience–related data to further understand RRMM treatment burden and better inform treatment decision-making.